Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Dianthus Therapeutics is a biotech company developing targeted complement system therapeutics for autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit active C1s, aiming for improved safety, efficacy, and convenience. The company focuses on diseases like myasthenia gravis, CIDP, and MMN, leveraging proprietary technology and strategic licensing to advance innovative, patient-friendly biologics.
This description was generated via AI from an annual report. Updated about 1 year ago.